Completed PHASE3 INTERVENTIONAL 2-arm NCT00549692

Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy (IgAN)

Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy

Sponsor: Kuhnil Pharmaceutical Co., Ltd.

Conditions IgA Nephropathy

Interventions Omega-3 fatty acid ethylester90

Updated 6 times since 2017 Last updated: Sep 25, 2012 Started: Nov 30, 2007 Primary completion: Aug 31, 2012 Completion: Sep 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00549692, this PHASE3 trial focuses on IgA Nephropathy and remains completed. Sponsored by Kuhnil Pharmaceutical Co., Ltd., it has been updated 6 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kuhnil Pharmaceutical Co., Ltd.
Pronova BioPharma ASA

Data source: Kuhnil Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seongnam, South Korea
• Seoul, South Korea